Number of shares and votes in Medivir

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Number of shares and votes in Medivir

PR Newswire

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during February 2021 as a result of the previously announced rights issue and over-allotment option and which in total resulted in an increase of 27,847,833 class B shares.

Today, the last trading day of the month, there are in total 52,135,651 shares in Medivir, of which all are class B shares with in total 52,135,651 corresponding voting rights.

For additional information, please contact
Yilmaz Mahshid, CEO
Telephone: +46 8 5468 3100
E-mail: [email protected]

Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: [email protected]

This information is such information that Medivir AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication on 26 February 2021 at 08:00 CET through the agency of the contact persons set out above.

Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. 
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/number-of-shares-and-votes-in-medivir,c3296336

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-medivir-301236305.html

SOURCE Medivir

Copyright CNW Group 2021

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).